scholarly journals PCN1 USE OF WHITE BLOOD CELL GROWTH FACTORS AND RISK OF ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROMES AMONG ELDERLY NON-HODGKIN'S LYMPHOMA PATIENTS

2010 ◽  
Vol 13 (3) ◽  
pp. A23
Author(s):  
SK Gruschkus ◽  
D Lairson ◽  
JK Dunn ◽  
JM Risser ◽  
XL Du
Keyword(s):  
Acute Myeloid Leukemia ◽  
Growth Factors ◽  
Cell Growth ◽  
Blood Cell ◽  
White Blood Cell ◽  
Myelodysplastic Syndromes ◽  
Myeloid Leukemia ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Acute Myeloid

Antiphospholipid Antibodies: Prevalence, Clinical Significance and Correlation to Cytokine Levels in Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma

1993 ◽  
Vol 70 (04) ◽  
pp. 568-572 ◽  
Author(s):  
Roberto Stasi ◽  
Elisa Stipa ◽  
Mario Masi ◽  
Felicia Oliva ◽  
Alessandro Sciarra ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Significance ◽  
Antiphospholipid Antibodies ◽  
Myeloid Leukemia ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Tnf Alpha ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Acute Myeloid

SummaryThis study was designed to explore the prevalence and clinical significance of elevated antiphospholipid antibodies (APA) titres in patients affected by acute myeloid leukemia (AML) and highgrade non-Hodgkin’s lymphoma (NHL). We also analyzed possible correlations with circulating levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and the soluble form of the receptor for interleukin-2 (sIL-2r). Nineteen patients with de novo AML and 14 patients with newly-diagnosed NHL were investigated. Tests for APA included the measurement of anticardiolipin antibodies (ACA) with a solid-phase immunoassay, and the detection of the lupus-like anticoagulant (LA) activity. Five patients with AML (26.3%) and 5 patients with NHL (35.7%) presented elevated APA at diagnosis, as compared to 3 of 174 persons of the control group (p <0.0001). APA titres became normal in all patients responding to treatment, whereas nonresponders retained elevated levels. In addition, 6 patients (4 with AML and 2 with NHL), who had normal APA at diagnosis and were either refractory to treatment or in relapse, subsequently developed LA and/or ACA positivity. At presentation, the mean levels of IgG- and IgM-ACA in patients were not significantly different from Controls, and concordance between ACA and LA results reached just 30%. With regard to the clinical course, we were not able to detect any statistically significant difference between patients with normal and elevated APA. Pretreatment concentrations of IL-6 and TNF-alpha in AML, and sIL-2r in NHL were found significantly elevated compared to Controls (p = 0.003, p = 0.009 and p = 0.024 respectively). In addition, the levels of these cytokines correlated with IgG-ACA at the different times of laboratory investigations. These results demonstrate that APA may have a role as markers of disease activity and progression in some haematological malignancies.

scholarly journals Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD

Haematologica ◽  
2011 ◽  
Vol 96 (9) ◽  
pp. 1310-1317 ◽  
Author(s):  
H. J. M. de Jonge ◽  
P. J. M. Valk ◽  
E. S. J. M. de Bont ◽  
J. J. Schuringa ◽  
G. Ossenkoppele ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Blood Cell ◽  
Cell Count ◽  
White Blood Cell Count ◽  
White Blood Cell ◽  
Myeloid Leukemia ◽  
Prognostic Impact ◽  
Intermediate Risk ◽  
Blood Cell Count ◽  
Acute Myeloid

scholarly journals Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia

2014 ◽  
Vol 3 (1) ◽  
pp. 17-20 ◽  
Author(s):  
Jacques Delaunay ◽  
Grzegorz Mazur ◽  
Mark Minden ◽  
Agnieszka Wierzbowska ◽  
Mark M. Jones ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Blood Cell ◽  
Cell Count ◽  
White Blood Cell Count ◽  
White Blood Cell ◽  
Older Patients ◽  
Myeloid Leukemia ◽  
Hepatic Function ◽  
Blood Cell Count ◽  
Acute Myeloid

scholarly journals Mathematical Models for the Influence of Cytarabine on White Blood Cell Dynamics in Acute Myeloid Leukemia

2018 ◽  
Author(s):  
Felix Jost ◽  
Enrico Schalk ◽  
Kristine Rinke ◽  
Thomas Fischer ◽  
Sebastian Sager
Keyword(s):  
Acute Myeloid Leukemia ◽  
Blood Cell ◽  
Mathematical Models ◽  
White Blood Cell ◽  
Myeloid Leukemia ◽  
Response Patterns ◽  
Consolidation Treatment ◽  
Wbc Count ◽  
The Impact ◽  
Acute Myeloid

AbstractWe investigate the personalisation and prediction accuracy of mathematical models for white blood cell (WBC) count dynamics during consolidation treatment using intermediate or high-dose cytarabine (Ara-C) in acute myeloid leukemia (AML). Ara-C is the clinically most relevant cytotoxic agent for AML treatment.We extend the gold-standard model of myelosuppression and a pharmacokinetic model of Ara-C with different hypotheses of Ara-C’s pharmacodynamic effects. We cross-validate 12 mathematical models using dense WBC count measurements from 23 AML patients. Surprisingly, the prediction accuracies are similarly good despite different modelling hypotheses. Therefore, we compare average clinical and calculated WBC recovery times for different Ara-C schedules as a successful methodology for model discrimination. As a result, a new hypothesis of a secondary pharmacodynamic effect on the proliferation rate seems plausible. Furthermore, we demonstrate how personalized predictions of the impact of treatment timing on subsequent nadir values could be used for clinical decision support.Author summaryThe major obstacle in accurately predicting the outcome of a medical therapy is the vast variation in individual response patterns. It concerns both the subjective experience of the patient and the objectively measurable achievement of a clinical remission with restoration of normal blood counts. Here, we address acute myeloid leukemia (AML)-chemotherapy using cytarabine (Ara-C) as this drug is this most important component of AML-treatment. In addition to the wide spectrum of genetic aberrations involved in pathogenesis leading to variations in patient response patterns, another facet of personalised medicine awaits exploration of its full potential: a systematic, mathematical approach to understand and manipulate the dynamics of relevant biomarkers. We use personalised mathematical models to describe and predict white blood cell (WBC) counts during AML consolidation treatment. We analyse why and to what extent low WBC counts, a serious adverse event during therapy, occur. In a comprehensive approach we investigate published models, compare them with our extended models and outline the impact of modelling assumptions and varying chemotherapy schedules on prediction accuracy and model discrimination. Our numerical results confirm the clinical finding that a newly proposed schedule is superior with respect to WBC recovery and shed new light on the reasons why.

Sign in / Sign up

Export Citation Format

Share Document